Omeros News

Omeros Corporation , a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the first quarter of 2013.

Omeros Corp issued its quarterly earnings data on Thursday. The company reported earnings per share for the quarter, missing the consensus estimate of by $0.01, StockRatingsNetwork reports.

Omeros Corporation today announced that it has agreed to sell 3,903,004 shares of its common stock at a price of $4.14 per share, a two percent premium over the closing price on May 8, 2013, for gross proceeds of $16.2 million.

OMS824 selectively inhibits phosphodiesterase 10 , an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease and schizophrenia.

OMS302, which contains mydriatic and anti-inflammatory agents, is the Company's product being developed for use during intraocular lens replacement, including cataract surgery and refractive lens exchange.

Data Show that OMS302 Maintains Pupil Size During Lens Replacement Surgery by Not Only Promoting Mydriasis but also by Preventing Miosis -- -- Data Show that OMS302 Maintains Pupil Size During Lens Replacement Surgery by Not Only Promoting Mydriasis but also by Preventing Miosis -- /PRNewswire/ -- Omeros Corporation today reported analyses of Phase ... (more)

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.omeros.com . Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system.